Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives $128.73 Average Target Price from Brokerages

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) have been assigned an average rating of “Moderate Buy” from the thirteen brokerages that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $128.7273.

Several research firms have recently weighed in on ABVX. Citigroup reiterated an “outperform” rating on shares of Abivax in a research note on Tuesday, December 16th. Guggenheim reaffirmed a “buy” rating and set a $175.00 price objective on shares of Abivax in a report on Thursday. Morgan Stanley increased their target price on shares of Abivax from $71.00 to $101.00 and gave the stock an “overweight” rating in a research report on Friday, September 12th. Wall Street Zen lowered shares of Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Abivax in a research note on Wednesday, October 8th.

Abivax Trading Up 20.7%

Shares of ABVX stock opened at $138.72 on Friday. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03. The firm has a market cap of $10.81 billion, a P/E ratio of -80.18 and a beta of 0.49. The company has a 50 day moving average of $109.59 and a 200-day moving average of $73.24. Abivax has a 12-month low of $4.77 and a 12-month high of $139.62.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings data on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The company had revenue of ($4.92) million during the quarter. Sell-side analysts anticipate that Abivax will post -2.83 earnings per share for the current year.

Hedge Funds Weigh In On Abivax

Hedge funds have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC lifted its holdings in Abivax by 4,612.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after purchasing an additional 369 shares in the last quarter. First Horizon Corp bought a new stake in shares of Abivax during the third quarter valued at about $36,000. Bank of America Corp DE lifted its holdings in shares of Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after buying an additional 1,990 shares in the last quarter. Hantz Financial Services Inc. purchased a new stake in shares of Abivax in the third quarter worth about $52,000. Finally, Cubist Systematic Strategies LLC boosted its position in shares of Abivax by 34.3% in the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock valued at $63,000 after acquiring an additional 2,595 shares during the period. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.